A recent study from the Children’s Research Institute, Departments of Pediatrics and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA shows that “Lin28b Is Sufficient to Drive Liver Cancer and Necessary for Its Maintenance in Murine Models.” This study was published in the August 11 2014 Cancer Cell (No.1 journal in basic cancer biology with an I.F of ~27.238) by Prof Zhu H, Nguyen LH, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for Hepatocelluar Carcinoma: MiRNA-101 inhibits liver cancer via down regulation of Lin28 and Igf2bp3. MiRNA-101, by decreasing the expression of its target gene, it may decrease tumor burden and prolong survival. Together, this study suggests that pharmacological formulations encompassing “MiRNA-101 or its activators” may be used to inhibit hepatocellular carcinoma.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, MiRNA-based therapy for Hepatocelluar Carcinoma: MiRNA-101 inhibits liver cancer via down regulation of Lin28 and Igf2bp3, 1/September/2014, 08.23 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
